Market Overview

10x Genomics Partners with BioLegend and Immudex to Extend Research Applications of Its New Single Cell Feature Barcoding Technology


Genomics, Inc
., a company focused on accelerating genomic discovery,
today announced that BioLegend
and Immudex
will be the first 10x
Compatible Partners
providing products for its new single cell Feature
Barcoding Technology
, which was revealed at the 2018 Advances in
Genome Biology and Technology meeting in February this year. The
resulting product innovations, available at the end of 2018, will enable
simultaneous gene and protein expression of the same cell as well as
cellular characterizations and mapping responses. The newly developed
applications have potential to accelerate disease research and drug
discovery in oncology, neurology, infections disease, and immunology in
addition to enhancing cell atlas research initiatives.

"We are proud to partner with 10x Genomics to commercialize this
groundbreaking method for multi-omic single cell analysis and to offer a
complete solution for researchers," stated Gene Lay, chief executive
officer of BioLegend. "Such high resolution and complex information can
be used to more deeply characterize highly heterogeneous cellular
populations and to further identify rare and important cells within
those populations. These insights can potentially lead to the
identification of novel molecular therapeutic targets and can accelerate
drug discovery in immuno-oncology, autoimmunity, neurodegeneration, and
other areas of human disease."

The co-development partnership with BioLegend will result in the first
commercially offered ready to use solution for simultaneous measurement
of highly-multiplexed protein and unbiased gene expression from single
cells, similar to previously reported academic methods, CITE-seq
and REAP-seq.
The new products offered by BioLegend, TotalSeq B and TotalSeq C, will
be fully compatible with 10x Genomics' Chromium Single Cell Gene
Expression Solution or Single Cell Immune Profiling Solution with
Feature Barcoding Technology.

The additional partnership with Immudex leverages its proprietary
Dextramer® technology to interrogate antigen-binding specificity
alongside the transcriptome and repertoire readouts at single cell
resolution. Using the 10x Chromium Single Cell Immune Profiling Solution
with new Feature Barcoding Technology and Immudex DNA barcoded
MHC-peptide multimers, researchers will be able to link full-length,
paired TCR alpha and beta chain sequences and transcriptional profiles
to the identity of their target antigens in the same cells with high
specificity and sensitivity.

"By combining our proprietary DNA barcoded Dextramer® technology with
10x Genomics Chromium System and Solutions, we now have the ability to
directly interrogate the TCR of the antigen-specific T Cells via
MHC-peptide binding along with simultaneous analysis of expressed genes
and cell surface phenotype for an entire sample at the single cell
level, which has not been possible with existing technologies," says
Liselotte Brix, chief scientific officer of Immudex.

"Through our 10x Compatible Product Partnership Program we are able to
rapidly extend our expanding portfolio of applications to our customers
worldwide," stated Brad Crutchfield, chief commercial officer of 10x
Genomics. "We seek out leading companies that complement our product
portfolio, establishing partnerships that provide our customers with
verified solutions. These partnerships are especially important as we
continue to grow at a rapid pace."

To learn more about Single Cell Feature Barcoding Technology, register
for these upcoming webinars:

More information about CITE-seq and REAP-seq can be found in the
following publications:

Customers interested in the Feature Barcoding Technology can find more
information at

Interested customers and potential partners can find more information
about the 10x Compatible Program at

About 10x Genomics

is building tools for scientific discovery that reveal and
address the true complexities of biology and disease. Through a
combination of novel microfluidics, chemistry and bioinformatics, our
award-winning Chromium System is enabling researchers around the world
to more fully understand the fundamentals of biology at unprecedented
resolution and scale.

Learn more at


About BioLegend

BioLegend develops and manufactures world-class, cutting-edge antibodies
and reagents at an outstanding value to customers for biomedical
research. The broad product portfolio includes flow cytometry, cell
biology, and functional reagents for research in immunology, cancer
research, stem cells, and more. The aggressive product development
program is accomplished through technology licensing, collaborations,
and internal research. BioLegend offers a wide range of custom services,
including assay development, sample testing, and conjugation. BioLegend
headquarters in San Diego, CA operates under an ISO 13485:2003 certified
quality management system. For more information on BioLegend, visit:

About Immudex

Based in Copenhagen, Denmark, with North American operations based in
Fairfax, Virginia, Immudex manufactures MHC Dextramer® for the detection
of antigen-specific T cells. Immudex's MHC Dextramer® products are
utilized for the quantification or sorting of antigen-specific T cells
in life science research, in vitro diagnostics, as well as the
development of immunotherapeutics and vaccines. The CE and FDA 510(k)
cleared Dextramer CMV Kit is approved for in vitro diagnostic use
for the quantification of CMV-specific T cells. GMP Grade reagents are

dCODETM DNA tagged Dextramer reagents enable massive
multiplexing of antigen-specific T cell detection via PCR and next
generation sequencing. To find out more about how Immudex is improving
immune monitoring please visit

View Comments and Join the Discussion!